Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10344023B2 · kind B2 · utility
6Cited by
11References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 23, 2015 |
| Grant date | Jul 9, 2019 |
| Priority date | — |
| Expiry date | Dec 23, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present disclosure is based, in part, on the discovery that disclosed compounds can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.